A Phase 1/2 Study of ANV419 as Monotherapy or in Combination With Anti-PD-1 or Anti-CTLA-4 Antibody Following Anti-PD-1/Anti-PD-L1 Antibody Treatment in Patients With Unresectable or Metastatic Cutaneous Melanoma

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Locations

CTRC Inpatient
Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Photograph of Laura Medina,  MD

Laura Medina, MD

Study ID

Protocol Number: 22-1121

More information available at ClinicalTrials.gov: NCT05578872

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers